• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文OA文献 >Risedronate prevents persistent bone loss in prostate cancer patients treated with androgen deprivation therapy: Results of a 2-year follow-up study
【2h】

Risedronate prevents persistent bone loss in prostate cancer patients treated with androgen deprivation therapy: Results of a 2-year follow-up study

机译：Risedronate prevents persistent bone loss in prostate cancer patients treated with androgen deprivation therapy: Results of a 2-year follow-up study

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Androgen deprivation therapy (ADT) for prostate cancer (PCa) causes bone loss. Although we reported previously that risedronate significantly recovers bone mineral density (BMD) for up to 12 months, there have been no reports with longer follow-up periods to date. This study extended our earlier series extending the follow-up period to 24 months. Eligible patients had histologically confirmed PCa without lumbar spine metastasis and underwent ADT. Lumbar spine BMD, urinary deoxypyridinoline (uDPD) and serum bone alkaline phosphatase were measured at 6, 12 and 24 months. Among the total of 96 patients, we analyzed 26 and 18 patients in risedronate administration and control groups, respectively. BMD relative to the young adult mean ratio, uDPD and serum bone alkaline phosphatase of the risedronate administration group recovered significantly after 24 months compared with the control group (P0.0001, P0.0001, and P0.0001, respectively). Transient blurred vision, malaise and vertigo were observed in 1 patient each among the 46 patients treated with risedronate within 28 days after first administration. Oral administration of risedronate is safe and effective for the recovery of ADT-induced bone loss in PCa patients even at 24 months after commencement of treatment. © 2011 Macmillan Publishers Limited All rights reserved.
机译：前列腺癌（PCa）的雄激素剥夺疗法（ADT）导致骨质流失。尽管我们之前曾报道瑞斯膦酸盐可在长达12个月的时间内显着恢复骨矿物质密度（BMD），但迄今为止，尚无报道涉及更长的随访时间。这项研究将我们之前的系列延长了随访时间，将其延长至24个月。符合条件的患者经组织学确认为PCa，无腰椎转移，并接受了ADT。在第6、12和24个月时测量腰椎骨密度，尿液脱氧吡啶啉（uDPD）和血清骨碱性磷酸酶。在总共96例患者中，我们分别分析了利塞膦酸盐治疗组和对照组的26例和18例患者。相对于对照组，BMD相对于年轻成年人的平均BMD，uDPD和血清骨碱性磷酸酶的水平在24个月后显着恢复（分别为P0.0001，P0.0001和P0.0001）。初次给药后28天内，在使用瑞思膦酸盐治疗的46例患者中，有1例观察到暂时性视力模糊，不适和眩晕。利塞膦酸盐的口服给药即使在开始治疗后的24个月内也能安全有效地恢复PCa患者的ADT诱导的骨丢失。 ©2011 Macmillan Publishers Limited版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号